{"filings":[{"id":655277,"accession_number":"0001193125-26-238237","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2026-05-26T15:00:21+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).","Liver weight reduced 43% (p<0.0001); lower ALT, AST, ALP and improved histology in treated animals.","Favorable body composition shift: fat -44.6% (grams), lean +17.2% as % body weight (high dose).","Cash and cash equivalents $0.354M as of March 31, 2026; runway into Q2 2026, needs additional financing.","Data from non-GLP mouse studies only; ALN1003 has not been tested in humans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":482519,"accession_number":"0001193125-26-227921","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2026-05-18T12:00:43+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alaunos announces preclinical ALN1003 data; cash only $0.354M, runway into Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALN1003 showed significantly lower HOMA-IR (p=0.0006) and higher adiponectin-to-leptin ratio in DIO mouse models.","Blinded liver histology: ALN1003-treated mice had mean NAS scores of 2.7 and 1.3 vs control score of 5.","Data are from non-GLP studies with small sample sizes; no human trials conducted yet.","Cash and equivalents $0.354M as of March 31, 2026; company seeking additional financing.","Plans to advance ALN1003 with further preclinical dose optimization and metabolic phenotyping."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91332,"accession_number":"0001193125-26-157126","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Alaunos Therapeutics receives Nasdaq delisting notice for equity shortfall; 45 days to submit plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Alaunos on April 9, 2026, of non-compliance with minimum $2.5M stockholders' equity; 2025 10-K reported $2.153M.","Company also fails alternative listing standards: market value of listed securities $35M or net income $500K last fiscal year.","Must submit compliance plan by May 26, 2026; if accepted, Nasdaq may grant up to 180-day extension.","If plan rejected or extension not achieved, Company may request hearing before Nasdaq hearings panel.","Trading in TCRT common stock continues pending disclosure and compliance process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101339,"accession_number":"0001193125-26-084084","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alaunos reports positive preclinical data for ALN1003; weight loss up to 12.9% in DIO mice","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ALN1003 showed dose-dependent body weight loss: -12.9% peak (Day 34) and -10.3% after 48 days vs DIO control (p<0.0001).","Liver weight reduced 43% (p<0.0001); liver enzymes ALT, AST, ALP significantly decreased in Study 1.","Highest-dose group lowered glucose to 197 mg/dL (vs 320 control) and total cholesterol to 162 mg/dL (vs 209).","Cash and equivalents ~$1.9M as of Sept 30, 2025; runway into Q2 2026; additional financing being pursued.","ALN1003 is an oral non-hormonal small molecule; company planning IND-enabling studies and next-gen compounds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101338,"accession_number":"0001193125-26-007054","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.02","3.03","8.01","9.01"],"status":"ready","headline":"Alaunos reports positive preclinical obesity data but cash runway only through Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preclinical DIO mouse study shows statistically significant dose-related weight loss and improved body composition; lead compound identified.","Cash and equivalents ~$1.9M as of Sep 30, 2025; runway only through Q1 2026; plans additional financing by end of Q1 2026.","Shareholder group with 8.6% stake requests Gerald W. Bruce as director; Corporate Governance Committee to review.","Terminated engagement with Cantor Fitzgerald as financial advisor; no fees paid, no strategic transaction consummated.","Amended bylaws with stockholder nomination advance notice requirements and universal proxy rule compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117708,"accession_number":"0001193125-25-331147","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Alaunos Therapeutics settles unpaid invoices with MD Anderson for $285,055","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement resolves disputes over $285,055 in unpaid invoices under 2019 R&D agreement with MD Anderson.","Alaunos to pay in six installments: $142,528 by Dec 30, 2025, then five monthly payments of $28,506 through May 30, 2026.","Mutual general releases exchanged for claims related to unpaid invoices; ongoing protocol 2006-0676 excluded.","CEO Holger Weis signed agreement on Dec 15, 2025; effective date Dec 17, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134145,"accession_number":"0000950170-25-110484","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Alaunos regains Nasdaq compliance after reporting $3.66M equity in Q2 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Alaunos of compliance on August 19, 2025, following prior stockholders' equity deficiency.","Company had reported $2.06M equity in 2024 10-K, below $2.5M minimum for continued listing.","Q2 2025 10-Q showed $3.66M equity, meeting Nasdaq's requirement; compliance plan submitted earlier.","Matter closed; no immediate delisting risk."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134144,"accession_number":"0000950170-25-097591","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alaunos Therapeutics Corporate Secretary Melinda Lackey to depart August 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Melinda Lackey notified company on 7/16/2025 of termination of consulting agreement effective 8/15/2025.","She will resign as Legal and Administrative Officer and Corporate Secretary on the effective date.","Departure not due to any disagreement with the company on operations, policies, or procedures.","No additional severance beyond accrued but unpaid compensation through effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134143,"accession_number":"0000950170-25-096656","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Alaunos Therapeutics appoints Michael A. Jerman as director, effective July 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jerman fills vacancy from Dale Curtis Hogue's resignation; also joins Audit and Compensation Committees.","Jerman replaces Holger Weis on committees after Weis became CEO; Jerman will chair Audit Committee.","Compensation: $40k annual cash retainer, plus committee fees; initial option for 10,000 shares vesting over 36 months.","Prorated annual grant of 3,200 shares awarded; vesting subject to continued service through 2026 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134142,"accession_number":"0000950170-25-095029","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["3.03","5.07","9.01"],"status":"ready","headline":"Alaunos shareholders approve 10x increase in authorized common shares, reverse split authorization","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increasing authorized common shares from 5M to 50M; amendment effective July 10, 2025.","Authorized reverse stock split at ratio between 1:5 and 1:20, at Board's discretion.","Stockholders approved raising shares available under 2020 Equity Incentive Plan from 130,745 to 1,130,745.","Elected directors: Robert W. Postma, Jaime Vieser, Holger Weis; Dale Hogue resigned before meeting and was not reelected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134141,"accession_number":"0000950170-25-093263","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Alaunos Therapeutics CEO resigns; Holger Weis appointed; audit committee shortfall triggers Nasdaq notice","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dale Curtis Hogue Jr. resigned as CEO and director effective July 1, 2025; no disagreement.","Holger Weis appointed CEO July 2, 2025; $275,000 base salary; option for 130,000 shares at $5.06.","Weis resigned from audit and compensation committees, causing non-compliance with Nasdaq Rule 5605(c); company intends to use 180-day grace period.","Hogue entered consulting agreement at $250/hour for strategic advisory services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150903,"accession_number":"0000950170-25-090202","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Alaunos Therapeutics raises ~$2.05M in registered direct offering of stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["338,725 shares at $3.36; 271,674 pre-funded warrants at $3.359/share.","Total gross proceeds ~$2.05M; offering closed June 24, 2025.","Net proceeds for general corporate purposes, including working capital and capex.","Offered under effective shelf registration statement (File No. 333-266841).","Pre-funded warrants have $0.001 exercise price; 4.99% or 9.99% beneficial ownership limit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150902,"accession_number":"0000950170-25-090201","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Alaunos Therapeutics raises $850K via private placement of Series A-2 Convertible Preferred Stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aggregate purchase price of $850,000 from accredited investors; offering closed June 24, 2025.","Each Series A-2 Preferred share priced at $1,000, convertible into common at $4.49 per share.","Preferred stock carries 10% annual dividend payable in additional Preferred shares.","Shares issued under Section 4(a)(2) and/or Rule 506(b), are restricted and not registered under Securities Act.","1,000 Series A-2 shares designated; 1,639,521 common shares outstanding prior to the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150901,"accession_number":"0000950170-25-083913","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Alaunos Therapeutics amends warrant with Mast Hill Fund, adds $0.57 floor price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Added floor price of $0.57 per share to exercise price adjustments in warrant issued May 19, 2025.","Removed requirement to adjust number of shares issuable upon dilutive issuance or variable price events.","Removed certain warrant holder rights in connection with fundamental transactions.","Amendment effective June 9, 2025; warrant originally issued concurrently with equity purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150900,"accession_number":"0000950170-25-077064","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Alaunos Therapeutics enters $25M equity purchase agreement with Mast Hill Fund","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mast Hill commits to buy up to $25M of common stock over 24 months at Company's discretion.","Company issued warrant to Mast Hill for 79,900 shares at $4.00 exercise price, 5-year term.","Minimum put $5K, max $500K per put or 20% of 5-day avg trading volume.","Shares subject to 4.99% beneficial ownership cap and Nasdaq 19.99% exchange cap unless stockholder approval.","Registration rights agreement requires filing registration statement within 60 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150899,"accession_number":"0000950170-25-055903","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Robert Hofmeister resigns from Alaunos Therapeutics board effective April 15, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Hofmeister, Ph.D., resigned from the board with immediate effect on April 15, 2025.","Resignation was not due to any disagreement on operations, policies, or practices.","No replacement has been named by the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150898,"accession_number":"0000950170-25-054309","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alaunos directors convert $139K deferred fees to equity: shares + options","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Total deferred board service fees of $139,000 from Q3 2024 through Q1 2025 converted to equity.","Issued 38,269 common shares with aggregate fair value of $111,750.","Granted 10,904 fully vested stock options at $2.92 exercise price, aggregate fair value $27,250.","Board elected equity over cash under Non-Employee Directors Compensation Policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150897,"accession_number":"0000950170-25-053523","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Alaunos raises $500K via Series A-1 Convertible Preferred to Watermill Asset Management","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["500 shares of Series A-1 Convertible Preferred at $1,000/share sold to Watermill Asset Management for $500K total.","Preferred shares carry 10% annual dividend payable in kind; convertible to common at $2.76 per share.","1,601,252 common shares outstanding; preferred votes with common on as-converted basis.","Closing occurred April 11, 2025; proceeds for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150896,"accession_number":"0000950170-25-053325","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["3.01","8.01"],"status":"ready","headline":"Alaunos receives Nasdaq deficiency notice for equity below $2.5M minimum; 45 days to submit plan","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $2.063M as of Dec 31, 2024, falls short of Nasdaq's $2.5M minimum under Rule 5550(b)(1).","Company has 45 days from Apr 7, 2025 to submit a compliance plan; if accepted, may have up to 180 days to cure.","Nasdaq also removed the one-year Panel Monitor that had been in place since February 2024.","The deficiency notice does not immediately affect listing, but non-compliance could lead to delisting.","Company intends to evaluate options and submit a plan to regain compliance within the allowed timeframe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186889,"accession_number":"0000950170-24-113960","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.02","2.02","9.01"],"status":"ready","headline":"Alaunos terminates key license with Precigen, pivots to oral obesity program; cash runway into Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.","Continues prosecuting TCR IP targeting KRAS, TP53, EGFR mutations and hunTR discovery platform.","Exploring strategic alternatives including acquisition, merger, reverse merger, or sale of assets.","Progressing internally developed small molecule oral obesity program; CMDO engaged for API manufacturing.","Cash runway extended into Q1 2025 via overhead reductions; in vitro testing planned Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203424,"accession_number":"0000950170-24-084024","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K/A","filed_at":"2024-07-17T23:59:59+00:00","items":["9.01","3.03","5.03"],"status":"ready","headline":"Alaunos Therapeutics files Charter Amendment for 1-for-10 reverse stock split effective July 17, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at ratio 1-for-10; effective July 17, 2024 at 5:00 p.m. ET.","Every 10 pre-split shares automatically converted to 1 post-split share; par value unchanged.","Stock continues trading on Nasdaq under symbol TCRT; new CUSIP number 98973P309 effective July 18.","Stockholders approved reverse split at June 6, 2024 annual meeting; board set final ratio on June 26, 2024.","Equiniti Trust Company appointed as exchange agent for the split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203423,"accession_number":"0000950170-24-084023","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K/A","filed_at":"2024-07-17T23:59:59+00:00","items":["9.01","8.01"],"status":"ready","headline":"Alaunos Therapeutics to effect 1-for-10 reverse stock split effective July 17, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-10 ratio; effective 5:00 p.m. Eastern on July 17, 2024.","Stock will trade split-adjusted on Nasdaq under symbol 'TCRT' starting July 18, 2024 with new CUSIP 98973P309.","Stockholder approval obtained at June 6, 2024 annual meeting; board set final ratio on June 26, 2024.","Equiniti Trust Company appointed as exchange agent to handle share conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203426,"accession_number":"0000950170-24-083765","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Alaunos Therapeutics effects 1-for-10 reverse stock split effective July 17, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective July 17, 2024 at 5:00 PM ET; every 10 pre-split shares become 1 post-split share.","Stockholders approved reverse split at June 6, 2024 annual meeting; board set 1-for-10 ratio on June 26, 2024.","Ticker TCRT unchanged; new CUSIP 98973P309; trading on split-adjusted basis from July 18, 2024.","Equiniti Trust Company appointed as exchange agent to handle shareholder share exchange."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203425,"accession_number":"0000950170-24-083764","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Alaunos Therapeutics to effect 1-for-10 reverse stock split on July 17, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-10 reverse split; authorized by shareholders on June 6, 2024.","Effective 5:00 p.m. ET July 17, 2024; every 10 pre-split shares become 1 share.","Stock to trade on Nasdaq under symbol TCRT with new CUSIP 98973P309.","Equiniti Trust Company appointed as exchange agent for the split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219821,"accession_number":"0000950170-24-076333","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Alaunos Therapeutics dismisses RSM, engages Cherry Bekaert as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed RSM US LLP as independent auditor on June 19, 2024; no disagreements reported.","Appointed Cherry Bekaert LLP as successor independent auditor effective June 19, 2024.","RSM's reports for FY 2023 and 2022 included going concern qualification.","Change approved by Audit Committee; no reportable events in prior periods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219820,"accession_number":"0000950170-24-072534","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["3.03","5.07","5.03","9.01"],"status":"ready","headline":"Alaunos shareholders approve reverse stock split (1:5-1:15) and authorized share increase to 50M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse stock split at ratio between 1-for-5 and 1-for-15, at Board's discretion, effective June 12, 2024.","Authorized shares of common stock increased from 34,666,667 to 50,000,000.","Five directors elected: Curtis Hogue Jr., Robert Hofmeister, Robert Postma, Jaime Vieser, Holger Weis.","Advisory vote on executive compensation passed with 1,851,846 for and 1,032,789 against.","Ratification of RSM US LLP as independent auditor for FY 2024 approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239595,"accession_number":"0001193125-24-042903","cik":1107421,"company_name":"Alaunos Therapeutics, Inc.","ticker":"TCRT","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Alaunos Therapeutics VP Finance resigns; Ferdinand Groenewald appointed as replacement via consulting agreement","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Wong resigned as VP Finance effective Feb 23, 2024.","Ferdinand Groenewald appointed as VP Finance effective Feb 22, 2024 via consulting agreement.","Consulting agreement pays $15,000 per month; indefinite term with 30-day termination notice.","Groenewald previously served as CFO and CAO of Muscle Maker, Inc.; is a CPA.","Agreement includes customary indemnification and business expense reimbursement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":68626230.60408163,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}